Skip to main content

Advertisement

SpringerLink
Log in

Aspirin in the treatment and prevention of cardiovascular disease: Current perspectives and future directions

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

In secondary prevention among male and female survivors of prior myocardial infarction (MI), occlusive stroke, transient ischemic attack, and other high-risk conditions, long-term use of aspirin confers very similar statistically significant and clinically important reductions in MI, stroke, and cardiovascular death. In men and women suffering acute MI or acute occlusive stroke, aspirin confers similar benefits. In primary prevention, aspirin confers a statistically significant and clinically important reduction in risk of a first MI, but the data on stroke and cardiovascular disease death remain inconclusive, so aspirin should be prescribed on an individual basis by the healthcare provider who weighs this clear benefit against long-term side effects. Worldwide, aspirin used more widely and appropriately would avoid many premature deaths in secondary prevention, during acute MI, and during acute stroke, as well as many first MI in primary prevention.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Williams A, Hennekens CH: The role of aspirin in cardiovascular diseases: forgotten benefits. Exp Opin Pharmacother 2004, 5:109–115.

    CAS  Google Scholar 

  2. American Heart Association: Heart Disease and Stroke Statistics — 2003 Update. Dallas, TX: American Heart Association.

  3. Murray CJ, Lopez AD: The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, MA: Harvard University Press; 1996.

    Google Scholar 

  4. Mackay J, Mensah G (editors): The Atlas of Heart Disease and Stroke. World Health Organization. Available at http://www.who.int/cardiovascular_diseases/resources/atlas/en/. Accessed on November 3, 2004.

  5. Doll R, Peto R, Boreham J, Sutherland I: Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ 2004, 328 1519–1528.

    Article  PubMed  Google Scholar 

  6. Peto R, Chen ZM, Boreham J: Tobacco—the growing epidemic. Nature Med 1999, 5:15–16

    Article  PubMed  CAS  Google Scholar 

  7. Liu BQ, Peto R, Chen ZM, et al.: Emerging tobacco hazards in China: 1. Retrospective proportional mortality study of one million deaths. BMJ 1998, 317:1411–1424

    PubMed  CAS  Google Scholar 

  8. Willett WC, Manson JE, Stampfer MJ, et al.: Weight and weight change in relation to risk of coronary heart disease in women: a 14-year follow-up. JAMA 1995, 273:461–465.

    Article  PubMed  CAS  Google Scholar 

  9. Flegal KM, Carroll MD, Ogden CL, Johnson CL: Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2002, 288:1723–1727.

    Article  PubMed  Google Scholar 

  10. Hennekens CH, Buring JE: Epidemiology in Medicine: Boston: Little, Brown, & Co; 1987.

    Google Scholar 

  11. Hennekens CH: Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. Circulation 1998, 97:1095–1102.

    PubMed  CAS  Google Scholar 

  12. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971, 231:232–235.

    PubMed  CAS  Google Scholar 

  13. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists’ Collaboration. BMJ 1988, 296:320–331.

  14. Antithrombotic Trialists’ Collaboration: Collaborative meta-analysis of randomized trials of antiplatlet therapy for prevention of death, myocardial infarction and stroke in high-risk patients. BMJ 2002, 324:71–86.

    Article  Google Scholar 

  15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2497.

    Article  Google Scholar 

  16. Hennekens CH, Sacks F, Tonkin A, et al.: Additive benefits of pravastatin and aspririn to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analysis. Arch Intern Med 2004, 164:40–44.

    Article  PubMed  CAS  Google Scholar 

  17. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction. ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988, 2:349–360.

  18. Hennekens CH, Jonas MA, Buring JE: The benefits of aspirin in acute myocardial infarction: still a well-kept secret in the U.S. Arch Intern Med 1994, 154:37–39.

    Article  PubMed  CAS  Google Scholar 

  19. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494–502.

    Article  Google Scholar 

  20. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group: Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005, 366:1607–1621.

    Article  PubMed  CAS  Google Scholar 

  21. The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 1997; 349:1569–81

  22. CAST: randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet 1997, 349:1641–1649.

  23. Steering Committee of the Physicians’ Health Study Research Group: Preliminary report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1988, 318:262–264.

    Article  Google Scholar 

  24. Steering Committee of the Physicians’ Health Study Research Group: Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989, 321:129–135.

    Article  Google Scholar 

  25. Peto R, Gray R, Collins R, et al.: Randomised trial of prophylactic daily aspirin in British male doctors BMJ 1988, 296:313–316.

    Article  PubMed  CAS  Google Scholar 

  26. Thrombosis prevention trial: randomised trial of low intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council’s General Practice Research Framework. Lancet 1998, 351:233–240.

  27. Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998, 351:1755–1762.

    Article  PubMed  CAS  Google Scholar 

  28. de Gaetano G; Collaborative Group of the Primary Prevention Project: Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001, 357:89–95.

    Article  PubMed  Google Scholar 

  29. Eidelman RS, Hebert PR, Weisman S, Hennekens CH: An update on aspirin in the primary prevention of cadiovascular disease. Arch Intern Med 2003, 163:2006–2010.

    Article  PubMed  Google Scholar 

  30. Ridker PM, Cook NR, Lee IM, et al.: A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005, 352:1293–1304

    Article  PubMed  CAS  Google Scholar 

  31. Levin RI: The puzzle of aspirin and sex. N Engl J Med 2005, 352:1366–1368.

    Article  PubMed  CAS  Google Scholar 

  32. Levin RI, Harpel PC, Weil D, et al.: Aspirin inhibits vascular plasminogen activator activity. J Clin Invest 1984, 74:571–580.

    Article  PubMed  CAS  Google Scholar 

  33. Becker DM, Segal J, Vaidya D, et al.: Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA 2006, 295:1420–1427.

    Article  PubMed  CAS  Google Scholar 

  34. Bartolucci AA, Howard G: Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 2006, 98:746–750.

    Article  PubMed  CAS  Google Scholar 

  35. Wilson PW, D’Agostino RB, Levy D, et al.: Prediction of coronary heart disease using risk factor categories. Circ 1998, 97:1837–1847.

    CAS  Google Scholar 

  36. United States Preventive Services Task Force: Aspirin for the primary prevention of cardiovascular events-recommendations and rationale. Ann Intern Med 2002, 136:157–160

    Google Scholar 

  37. Pearson TA, Blair SN, Daniels SR, et al.: American Heart Association guidelines for primary prevention of cardiovascular disease and stroke: 2002 Update: Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 1998, 106:388–391.

    Article  Google Scholar 

  38. Garcia Rodriguez LA, Hernandez-Diaz S, de Abajo FJ: Association between aspirin and upper gastrointesitinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol 2001, 52:563–571.

    Article  PubMed  CAS  Google Scholar 

  39. Nelson M, Rerid C, Beilin L, et al.; Aspirin in Reducing Events in the Elderly (ASPREE) Study Group: rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Drugs Aging. Drugs Aging 2003, 20:897–903.

    Article  PubMed  CAS  Google Scholar 

  40. Hennekens CH, Hollar D, Baigent C: Sex related differences in response to aspirin: an untested hypothesis. Nat Clin Pract Cardiovasc Med 2006, 3:4–5.

    Article  PubMed  Google Scholar 

  41. Thomas Henry Huxley: Science is organized common sense where many a beautiful theory was killed by an ugly fact. Available at http://www.brainyquote.com/quotes/authors/t/Thomas_henry_huxley.html. Accessed on January 27, 2007.

  42. Patrono C, Bachmann F, Baigent C, et al.; European Society of Cardiology: Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 2004, 25:166–181.

    Article  PubMed  Google Scholar 

  43. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. UK-TIA Study Group. BMJ 1988, 296:316–320.

  44. Reilly IA, FitzGerald GA: Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987, 69:180–186.

    PubMed  CAS  Google Scholar 

  45. Hennekens CH, Sechenova O, Hollar D, Serebruany V: Dose of aspirin in the treatment and prevention of cardiovascular disease; current and future directions. J Cardiovasc Pharm Ther 2006, 11:1–7.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 2800 South Ocean Boulevard PHA, Boca Raton, FL, 33432, USA

    Charles H. Hennekens MD

Authors
  1. Charles H. Hennekens MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charles H. Hennekens MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hennekens, C.H. Aspirin in the treatment and prevention of cardiovascular disease: Current perspectives and future directions. Curr Atheroscler Rep 9, 409–416 (2007). https://doi.org/10.1007/s11883-007-0053-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-007-0053-0

Keywords

Search

Navigation